Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jeremy Baker

Physician Assistant, Medical Hartford, CT Physician Assistant

NPI 1295373785 CMS profile 10811260

19 Woodland St Ste 23, Hartford, CT 06105

Open in the dashboard

General payments

$7,664

369 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeremy Baker of Hartford, CT is reported in the CMS Open Payments database as having received $7,664 across 369 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,705 122
2024 General $2,330 101
2023 General $1,287 61
2022 General $638 29
2021 General $703 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Baker
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jeremy Baker were reported at $2,705. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jeremy Baker Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $703 $156 $41–$563 $132
2022 $638 $185 $55–$649 $149
2023 $1,287 $199 $58–$717 $160
2024 $2,330 $206 $62–$740 $164
2025 $2,705 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $1,050 40 payments
  2. Amgen Inc. $502 24 payments
  3. AbbVie, Inc. $466 43 payments
  4. Lilly USA, LLC $457 18 payments
  5. Novo Nordisk Inc $379 26 payments
  6. AstraZeneca Pharmaceuticals LP $348 19 payments
  7. GlaxoSmithKline, LLC. $276 12 payments
  8. Allergan Inc. $249 12 payments
  9. Myriad Genetic Laboratories, Inc. $204 13 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $192 8 payments
  11. Other $3,541 154 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,664 369 payments
Products named General payments · program years 2021–2025
  1. FreeStyle Libre 3 $1,050 40 payments
  2. UBRELVY $352 35 payments
  3. Prolia $333 16 payments
  4. EVENITY $326 16 payments
  5. AIRSUPRA $276 15 payments
  6. MOUNJARO $257 9 payments
  7. Ozempic $253 17 payments
  8. BOTOX $220 11 payments
  9. ZEPBOUND $210 7 payments
  10. TRELEGY ELLIPTA $207 9 payments
  11. Other $5,691 263 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

2,043

Median for Physician Assistant: 241

Drug cost

$1,314,694

Median for Physician Assistant: $4,110

Branded share of claims

71.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 128 $228,207
Trulicity Dulaglutide Brand 102 $169,377
Jardiance Empagliflozin Brand 72 $98,763
Mounjaro Tirzepatide Brand 58 $93,357
Prolia Denosumab Brand 53 $91,371
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 49 $87,962
Januvia Sitagliptin Phosphate Brand 51 $75,563
Farxiga Dapagliflozin Propanediol Brand 63 $74,403
Tresiba Flextouch U-200 Insulin Degludec Brand 51 $72,042
Tresiba Flextouch U-100 Insulin Degludec Brand 80 $51,650

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$25,098

Medicare's payments for the services billed

Medicare patients

131

Average age 76

Services billed

814

91 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 65%
Arthritis 49%
Osteoporosis 40%
Ischemic heart disease 35%
Chronic kidney disease 33%
Depression 32%
Cancer 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $157
$157 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $142
$142 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $71
  • Lilly USA, LLC $67
$138 72 —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $95
$95 — —
Korlym
  • Corcept Therapeutics $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

369 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record